NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal Cancer
 
Sponsors and Collaborators
Nektar Therapeutics
 
Contact
Robert Medve, MD
415-482-5300
 
Charleen Jue, B.S.
415-482-5300
 
ClinicalTrial.gov Identifier